defactinib (VS-6063)

defactinib · Verastem, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for defactinib (VS-6063), covering 2015-11-20 to 2026-04-02. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer [Phase 3]